Hepatitis C

Type: Keyphrase
Name: Hepatitis C
First reported 12 hours ago - Updated 1 hour ago - 12 reports

Daclatasvir (Daklinza) for Chronic Hepatitis C Cleared in EU

The European Commission has approved daclatasvir ( Daklinza , Bristol-Myers Squibb) to treat adults with chronic hepatitis C virus (HCV) infection in combination with other drugs, the company announced today.The approval follows an endorsement in June ... [Published General Medicine eJournal - 1 hour ago]
First reported 6 hours ago - Updated 2 hours ago - 6 reports

Ryogen LLC Awarded Two U.S. Patents Directed To Hepatitis C And Diabetes

SUFFERN, N.Y.--(BUSINESS WIRE)--Ryogen LLC, an R&D company focusing on polynucleotide sequences implicated in human diseases, was awarded two new patents, bringing the total number of its issued U.S. Patents to 34.U.S. Patent No. 8,795,959 titled “Isolated ... [Published BioSpace - 2 hours ago]
First reported 3 hours ago - Updated 3 hours ago - 1 reports

UNM Health Sciences gets grant to study hepatitis C

The Health Science Center at the University of New Mexico has received a $1.3 million grant from the CDC to study the prevalence of hepatitis C among young needle-drug users in rural New Mexico.Dr. Kimberly Page, the chief of epidemiology, biostatistics ... [Published Business First of Buffalo - 3 hours ago]
First reported 4 hours ago - Updated 4 hours ago - 1 reports

32 of 33 Exeter hepatitis C lawsuits settled

BRENTWOOD — Two years after a hepatitis C outbreak rocked Exeter Hospital, attorneys have settled 32 of the 33 lawsuits brought against the hospital and other agencies by infected patients.Nearly a dozen lawyers representing the hospital, insurance companies, ... [Published Exeter NewsLetter - 4 hours ago]
First reported 10 hours ago - Updated 10 hours ago - 1 reports

Health experts call for action to halt hepatitis epidemic

High rates of hepatitis C across Maribyrnong and Hobsons Bay heighten the urgency for immediate action from Victorian politicians, health experts warned at a conference in Footscray on Friday.Hepatitis specialists are calling for rapid testing to be introduced ... [Published Maribyrnong Weekly - 10 hours ago]
First reported Aug 26 2014 - Updated 12 hours ago - 2 reports

UNM gets grant to study rise in rural Hepatitis C

The University of New Mexico Health Sciences Center is getting a $1.3 million grant to study the rise of Hepatitis C infections in rural New Mexico.Click to Continue » ... [Published Kentucky.com - 12 hours ago]
First reported 18 hours ago - Updated 18 hours ago - 1 reports

Avera Medical Minute AMcK: Hepatitis C Screening

It's a virus that has infected more than three million Americans, many of whom don't even know they're infected. You've probably heard of Hepatitis C but what is it exactly and is it treatable?It's nobody's favorite thing to do but Rodney Geurtz has gotten ... [Published KSFY - 18 hours ago]
Entities: Hepatitis C, Avera, Virus
First reported Aug 26 2014 - Updated Aug 26 2014 - 2 reports

Gilead: Earnings Forecast Justifies $140 Price Target

By Leonard Yaffe :I have been recommending Gilead (NASDAQ: GILD ) for the past 3 years, and for the past 2 years my price target has been $140. Below, I shall discuss the company's current earnings stream, largely driven by Hepatitis C , as well as a ... [Published BioPortfolio - Aug 26 2014]
First reported Aug 25 2014 - Updated Aug 26 2014 - 2 reports

Gilead Wins Dispute with Rival Roche Over Rights to Sovaldi

Gilead Sciences may continue marketing its blockbuster hepatitis C drug Sovaldi after winning a dispute with rival drugmaker Roche over rights to the expensive new therapy.A U.S. arbitration panel last week disagreed with Roche’s March 2013 claims ... [Published FDA News - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 2 reports

What you need to know about hepatitis

Did you know that Hepatitis C, a serious liver disease, is known as a silent disease, since people often don’t know that they are infected?Prevention of hepatitis is preferable, as the chronic form of this infection is difficult to treat and has a potentially ... [Published All4Women - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Healthy Trucking Association Launches Hepatitis C Initiative

The Healthy Trucking Association of America, in conjunction with OraSure Technologies and AbbVie, has launched the Truckers Rolling Against Hepatitis C nationwide initiative.The initiative is meant to educate truck drivers about the hepatitis C virus ... [Published Trucking Info - Aug 26 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 2 reports

Slaying the sleeping dragon

Estimated over 100,000 Australians unaware they have hepatitisImage: Hepatitis Australia’s Helen Tyrell looks over the factsEvery year, more than 1 million people die from diseases caused by hepatitis B & and hepatitis C (the two most serious of the five ... [Published Ten Network - Aug 25 2014]

Quotes

Daclatasvir is the first NS5A complex inhibitor approved in the European Union (EU) and, in combination with other drugs, provides a "shorter treatment duration (12 or 24 weeks) compared to 48 weeks of treatment with interferon- and ribavirin-based regimens" the company says
Dr McIntyre said: "The amount of work carried out by scientists on a particular disease is a good indication of how much of a threat it is. This approach is a quick and accurate method of aggregating the work carried out by thousands of scientists around the world and using it to guide policy at a continent-wide level."
But here's the kicker: "[N]ear-term competitors that offer favorable pricing ... will likely be a constraint on the uptake of [Gilead's] regimen" Decision Resources said. Which means that rivals that undercut Gilead's price might move ahead in the prescribing queue...
...Emmanuel Blin, head of worldwide commercialisation at Bristol-Myers Squibb, remarked "we look forward to our continued work with EU health authorities to ensure Daklinza-based regimens are available to patients as quickly as possible."

More Content

All (2699) | News (2107) | Reports (0) | Blogs (555) | Audio/Video (1) | Fact Sheets (12) | Press Releases (16)
sort by: Date | Relevance
Daclatasvir (Daklinza) for Chronic Hepatitis C ... [Published General Medicine eJournal - 1 hour ago]
Gilead, Jazz Among 4 Top Big Cap Medicals To… [Published Investor's Business Daily - 2 hours ago]
Ryogen LLC Awarded Two U.S. Patents Directed To... [Published BioSpace - 2 hours ago]
UNM Health Sciences gets grant to study hepatit... [Published Business First of Buffalo - 3 hours ago]
10 things to know about specialty drug spending [Published Beckers Hospital Review - 3 hours ago]
BMS' Daklinza Approved in Europe for Chronic He... [Published Genetic Engineering News - 3 hours ago]
Healthy Earnings Growth Sustains Pricey Biotech... [Published Yahoo! Finance - 3 hours ago]
Bristol-Myers Squibb hepatitis C drug cleared f... [Published MedCity News - 3 hours ago]
Geisinger researcher nominated for federal awar... [Published Orthopedics Today - 4 hours ago]
32 of 33 Exeter hepatitis C lawsuits settled [Published Exeter NewsLetter - 4 hours ago]
EU green light for B-MS hepatitis C drug [Published Pharma Times - 4 hours ago]
Big data approach identifies Europe's most dang... [Published EurekAlert! - 5 hours ago]
Ryogen Awarded Two U.S. Patents Directed to Hep... [Published Fort Mills Times - 6 hours ago]
Health exchange premiums will drop [Published NEMS 360 - 6 hours ago]
Ryogen Awarded Two U.S. Patents Directed to Hep... [Published EON Science - 6 hours ago]
Ryogen Awarded Two U.S. Patents Directed to Hep... [Published Pettinga Financial Advisors - 6 hours ago]
Ryogen Awarded Two U.S. Patents Directed to Hep... [Published Business Wire Science: Science News - 6 hours ago]
Ryogen Awarded Two U.S. Patents Directed to Hep... [Published Business Wire Health News - 6 hours ago]
Here’s How The Rest Of The Year Will Hold Up Fo... [Published Bidness Etc - 7 hours ago]
Bristol-Myers gets the approval Gilead didn't w... [Published FiercePharma - 8 hours ago]
US FDA approves GSK's sNDA for Promacta for use... [Published PharmaBiz - 9 hours ago]
Bristol-Myers Squibb's hepatitis C therapy Dakl... [Published FirstWord Pharma - 10 hours ago]
Health experts call for action to halt hepatiti... [Published Maribyrnong Weekly - 10 hours ago]
Bristol-Myers: EU Approves Daklinza For Treatin... [Published FinanzNachrichten.de - 10 hours ago]
Bristol-Myers Says Daklinza Gets EU Approval Fo... [Published FinanzNachrichten.de - 11 hours ago]
European Commission Approves Bristol-Myers Squi... [Published Fort Mills Times - 11 hours ago]
Bristol-Myers Says Daklinza Gets EU Approval Fo... [Published RTTNews.com - 11 hours ago]
European Commission Approves Bristol-Myers Squi... [Published Digital Journal - 12 hours ago]
UNM gets grant to study rise in rural Hepatitis C [Published Kentucky.com - 12 hours ago]
European Commission Approves Bristol-Myers Squi... [Published Good Day Sacramento - 12 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Ryogen Awarded Two U.S. Patents Directed to Hep... [Published EON Science - 6 hours ago]
SUFFERN, N.Y.--(EON: Enhanced Online News)--Genomics R&D firm, Ryogen LLC, has been awarded two U.S. Patents – its 33rd and 34th – that are directed to polynucleotide sequences that play critical roles in Diabetes and Hepatitis C. ...
Ryogen Awarded Two U.S. Patents Directed to Hep... [Published Business Wire Science: Science News - 6 hours ago]
SUFFERN, N.Y.--(BUSINESS WIRE)--Genomics R&D firm, Ryogen LLC, has been awarded two U.S. Patents – its 33rd and 34th – that are directed to polynucleotide sequences that play critical roles in Diabetes and Hepatitis C. ...
Ryogen Awarded Two U.S. Patents Directed to Hep... [Published Business Wire Health News - 6 hours ago]
SUFFERN, N.Y.--(BUSINESS WIRE)--Genomics R&D firm, Ryogen LLC, has been awarded two U.S. Patents – its 33rd and 34th – that are directed to polynucleotide sequences that play critical roles in Diabetes and Hepatitis C. ...
European Commission Approves Bristol-Myers Squi... [Published Business Wire Health News - 12 hours ago]
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with ...
September live chats - from Cleveland Clinic [Published HealthBoards - Aug 26 2014]
We have many exciting live online web chats scheduled for September. Take advantage of this rare opportunity to chat live with Cleveland Clinic health care professionals. Chats are free and occur at 12 noon EST - http://chat.clevelandclinic.org/ (copy ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
GM Puts Engineers On Leave [Published Wall Street Journal What's News - Apr 10 2014]
1

Press Releases

sort by: Date | Relevance
Screening and Drug Therapy Predicted to Make He... [Published GlobeNewswire: Advertising News - Aug 05 2014]
U.S. FDA has granted Priority Review for OLYSIO... [Published GlobeNewswire: Advertising News - Jul 15 2014]
European Medicines Agency Validates Marketing A... [Published Financial Services - Jun 17 2014]
OraSure Technologies Announces New Co-Promotion... [Published GlobeNewswire: Advertising News - Jun 11 2014]
OLYSIO™ available soon in all Nordic countries ... [Published GlobeNewswire: Acquisitions News - Jun 10 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.